Xeris Biopharma Holdings, Inc.
XERS
$5.48
-$0.25-4.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 316.72% | 103.95% | 87.15% | 51.42% | 61.81% |
| Total Depreciation and Amortization | 2.04% | 2.08% | 0.32% | -2.21% | -3.87% |
| Total Amortization of Deferred Charges | 5.10% | 4.98% | 1.61% | 47.29% | 56.36% |
| Total Other Non-Cash Items | 46.24% | 169.88% | 22.65% | 749.52% | 926.83% |
| Change in Net Operating Assets | 21.31% | 810.39% | -103.19% | -64.05% | -102.71% |
| Cash from Operations | 914.84% | 321.94% | 101.76% | 50.59% | -73.56% |
| Capital Expenditure | -51.36% | 18.39% | 29.72% | 92.07% | -66.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -31.76% |
| Cash from Investing | -103.32% | -100.72% | -106.06% | 99.93% | -32.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 125.89% | -- | 153.80% | 959.04% | -- |
| Repurchase of Common Stock | -827.71% | -475.90% | -1,586.27% | -132.91% | -238.78% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -166.83% | 16,786.75% | 42.94% | -108.91% | 132.25% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.95% | 2,010.81% | 116.61% | -176.97% | -41.30% |